The Impact of Spliceosome Inhibition in SF3B1 -Mutated Uveal Melanoma
Investigative Ophthalmology & Visual Science · 2024
DOI: 10.1167/iovs.65.12.11 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2024. Written by Josephine Q N Nguyen and 12 co-authors. Institution: Department of Ophthalmology, Erasmus MC Cancer Institute, Erasmus MC Medical Center Rotterdam, CA Rotterdam, The Netherlands. Major MEDLINE topics: RNA Splicing Factors, Uveal Neoplasms, Melanoma, Spliceosomes. Cited 7 times so far (Crossref); 67 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Purpose
Unfortunately, treatment of patients with uveal melanoma (UM) with metastatic disease is limited. Twenty percent of patients with UM harbor a mutation in the splicing factor gene SF3B1, suggesting that aberrant spliceosome function plays a vital role in tumorigenesis. Splicing inhibitors exploit the preferential sensitivity of spliceosome-compromised leukemic cells to these compounds.
Methods
We studied the effect of the splicing inhibitor E7107 using two UM cell lines and ex vivo cultured SF3B1- and BAP1-mutated primary UM tumor slices. These UM cell lines and ex vivo tumor slices were exposed for 24 hours to different concentrations of E7107. Tumor slices were stained with hematoxylin and eosin (H&E) and incubated with BAP1, MelanA, MIB-1, and caspase-3 antisera.
Results
The E7107-exposed UM cell lines exhibited decreased cell viability and increased apoptosis, with the greatest effect on SF3B1-mutated UM cells. A similar effect on UM tumor slices was observed upon exposure to E7107. Additionally, RNA was isolated for differential isoform expression analysis. No significant difference in isoform usage was found genome-wide. However, specific genes were differentially expressed after E7107 treatment in the SF3B1-mutated samples. Moreover, E7107 had the greatest effect on intron retention.
Conclusions
This study indicates/suggests that mutated SF3B1 UM cells are more sensitive to the splicing inhibitor E7107 than wild-type SF3B1 UM cells.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Erasmus MC Cancer Institute, Erasmus MC Medical Center Rotterdam, CA Rotterdam, The Netherlands.
- Department of Clinical Genetics, Erasmus MC Cancer Institute, Erasmus MC Medical Center Rotterdam, CA Rotterdam, The Netherlands.
- The Rotterdam Eye Hospital, BH Rotterdam, The Netherlands.
- Department of Pathology, Section Ophthalmic Pathology, Erasmus MC Cancer Institute, Erasmus MC Medical Center Rotterdam, CA Rotterdam, The Netherlands.
- Department of Pathology, Leiden University Medical Center, ZA Leiden, The Netherlands.
- Cancer Computational Biology Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam, CA Rotterdam, The Netherlands.
Cite
APA
Nguyen, J. Q. N., Drabarek, W., Leeflang, A. M. C. H. J., Brands, T., van den Bosch, T. P. P., Verdijk, R. M., van de Werken, H. J. G., van Riet, J., Paridaens, D., de Klein, A., Brosens, E., Kiliç, E., & Rotterdam Ocular Melanoma Study Group (2024). The Impact of Spliceosome Inhibition in SF3B1 -Mutated Uveal Melanoma. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.65.12.11
Vancouver
Nguyen JQN, Drabarek W, Leeflang AMCHJ, Brands T, van den Bosch TPP, Verdijk RM, et al. The Impact of Spliceosome Inhibition in SF3B1 -Mutated Uveal Melanoma. Investigative Ophthalmology & Visual Science. 2024. doi:10.1167/iovs.65.12.11
BibTeX
@article{Nguyen2024,
author = {Nguyen, Josephine Q N and Drabarek, Wojtek and Leeflang, Aïsha M C H J and Brands, Tom and van den Bosch, Thierry P P and Verdijk, Robert M and van de Werken, Harmen J G and van Riet, Job and Paridaens, Dion and de Klein, Annelies and Brosens, Erwin and Kiliç, Emine and Rotterdam Ocular Melanoma Study Group, Rotterdam Ocular Melanoma Study Group},
title = {The Impact of Spliceosome Inhibition in SF3B1 -Mutated Uveal Melanoma},
journal = {Investigative Ophthalmology & Visual Science},
year = {2024},
doi = {10.1167/iovs.65.12.11}
}
EUVIMED